Performance & longevity
Systemic IV protocols for healthy adults pursuing measurable recovery, athletic performance, and longevity work. The most aspirational regenerative use case — and the one where managing expectations matters most.
- Class
- Longevity · systemic
- Approach
- IV systemic, periodic dosing
- Materials
- MSC · exosome
- Workup
- Diagnostic-led baseline
01 About
What "longevity" means at Apex.
"Longevity" in the regenerative-medicine context covers a different patient than the joint or systemic-disease indications: typically a healthy adult who is not seeking to treat a specific diagnosis but to support recovery, modulate the chronic inflammation that accumulates with aging, and proactively address frailty risk. The goal is not to add years — it is to support the function of the years you have.
This is also the indication where it is easiest to oversell. We are explicit: cellular therapy is not a fountain of youth, not a guarantee of any particular outcome, and not a substitute for sleep, nutrition, exercise, and primary-care management. It is one tool — for the right patient, with measurable baselines, and clear reassessment criteria.
02 How it works
How regen supports the system.
Mesenchymal stem cells delivered systemically modulate the chronic, low-grade inflammation associated with aging — sometimes called "inflammaging" — through their characteristic paracrine effects. They release exosomes carrying anti-inflammatory and pro-regenerative signals across multiple tissues. Animal and primate studies show systemic reductions in cellular senescence and tissue degeneration with periodic dosing.
For longevity, the data we anchor on is the frailty evidence — phase 2 trials in age-related physical frailty have shown improvements in physical function and reductions in inflammatory markers. Whether these effects extend to broader healthspan in healthy adults is a hypothesis being actively studied, not yet a proven outcome.
03 What the research shows
What the studies show.
The longevity-specific evidence base anchors on age-related frailty. Direct healthspan or lifespan trials in healthy adults are still preliminary. We are explicit about this distinction.
Lomecel-B (Allogeneic MSCs) for Aging Frailty
A phase 2b randomized trial of intravenous allogeneic MSCs (Lomecel-B / laromestrocel) in older adults with age-related frailty showed improvements in physical function compared with placebo at 9 months — alongside reductions in inflammatory markers and improvements in quality-of-life scores. The strongest direct evidence for cellular therapy in aging-related decline.
Read on LongeveronRecent Clinical Trials with Stem Cells to Slow or Reverse Normal Aging Processes
A 2023 review of clinical trials of MSC therapy for aging-related conditions. The review summarizes the developing evidence base — strongest for physical frailty and facial skin aging — and discusses the rationale for systemic IV cellular therapy as an adjunct to lifestyle and primary-care management.
Read on PubMed CentralSenescence-Resistant Human MSCs Counter Aging in Primates
A 44-week primate study of intravenous senescence-resistant cells (SRCs) in aged macaques showed systemic reductions in cellular senescence, chronic inflammation, and tissue degeneration markers — with no detected adverse effects. The strongest preclinical signal to date for systemic cellular therapy in aging.
Read on Cell
Longevity is the indication where we are most explicit about evidence vs. expectation. The data is real but preliminary. We will tell you what we expect — modest functional improvements, lower inflammation — and what we don't expect, which is reversal of aging or guaranteed life-extension.
04 Are you a candidate
Who's a candidate.
Candidates:
- Healthy adults pursuing measurable recovery, athletic performance, or longevity work.
- Adults with elevated inflammatory markers despite optimized lifestyle.
- Patients with early frailty markers (reduced grip strength, gait speed) seeking adjunct therapy.
- Patients willing to commit to baseline diagnostics and follow-up reassessment.
When we will not recommend it:
- Patients seeking guaranteed outcomes — that's not what the data supports.
- Active malignancy or recent cancer history (consult oncology first).
- Patients who haven't optimized the foundation: sleep, nutrition, training, primary-care management.
- Patients seeking longevity protocols as a substitute for evidence-based preventive medicine.
Think you might be a candidate?
The first step is a 60–90 minute consultation. We review your imaging, history, and goals — and tell you honestly whether regenerative therapy is the right next step.
05 A patient experience
Dr. Abdullah did an amazing job treating both me and my spouse. I feel less pain every day, and my brain fog is entirely gone. It's only been about 3 weeks.
Kayla Google · Local Guide
07What happens at your consultation
A conversation, not a sales meeting.
-
01
Intake & history
60–90 minutes. We review imaging, prior treatments, current medications, and goals. Most of this hour is listening.
-
02
Focused exam
A clinical exam tailored to your indication. Range of motion, strength, functional testing — what the literature actually predicts response on.
-
03
Honest candidacy review
If we think you're a candidate, we'll tell you why. If we don't, we'll tell you what we'd recommend instead — surgery, PT, watchful waiting.
-
04
Written plan & pricing
A defined treatment plan with modality, sequence, follow-up cadence, and total cost — before any commitment.
06 What treatment looks like
What treatment looks like.
A longevity protocol begins with a comprehensive baseline workup — labs (CBC, CMP, lipids, hormone panel, hsCRP, HbA1c), body composition, functional testing (grip strength, gait speed). Treatment is IV systemic MSC and/or exosome material in a periodic schedule — typically a series of doses spaced over months, with maintenance dosing thereafter.
Reassessment at 3, 6, and 12 months. Repeat labs, functional metrics, and biological-age proxies (if measured). The protocol is iterative — we adjust based on what your data shows.
09 Common questions
Common questions, answered.
Will this extend my life?
That's not what the data shows. The evidence supports improved physical function and reduced inflammation — measurable healthspan, not lifespan.
Who is this for?
Healthy adults pursuing measurable optimization, with realistic expectations and a commitment to baseline diagnostics. Not a magic intervention.
How often should I redose?
Periodic — typically annually after an initial loading series. Depends on baseline labs and ongoing biomarker tracking.
What does 'baseline' actually look like?
Comprehensive labs (CBC, CMP, lipids, hormones, hsCRP, HbA1c), body composition, functional testing, biological-age proxies. We measure before treating.
Should I do this if I'm already healthy?
Possibly. The strongest data is in early frailty markers (reduced grip strength, gait speed). Healthy-baseline patients often see modest gains in inflammation and recovery.
What are the risks?
IV MSC protocols are well-tolerated in the frailty trial data. Brief post-infusion fatigue is the most common minor effect.
08 Coverage & cost
Most regenerative protocols at Apex are not covered by insurance — we discuss pricing directly, in writing, before any commitment. Softwave shockwave is the exception: covered by Medicare Parts A & B with supplement (not by Medicare Advantage). Financing options are available for protocols not covered. We never hold a pricing conversation until we know you're a candidate.
Begin with a consultation.
A frank conversation about your goals, your baseline, and whether IV MSC or exosome therapy is a sensible next step — and what realistic, measurable outcomes look like for your situation.